Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus
PDAOAI PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus AGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE)...
Melanoma
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera...
Werewolf Therapeutics Announces Pipeline and Business Updates
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of...
Werewolf Therapeutics Announces Pipeline and Business Updates
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of...
CNS Pharmaceuticals Announces CEO Transition
Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17,...
Landmark Study Shows Combination of Castle Biosciences’ DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests...
Medical Care Technologies, Inc. (OTC Pink:MDCE) Completes First AI Consumer App Targeting Deployment Across 100+ Countries and 30 Languages
Company to Launch AI Food & Recipe App to Access Trillion-Dollar Global Food Market While Advancing Medical AI Pipeline MESA,...
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that...
Plus Therapeutics Expands CNSide Assay Platform to State of California
CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)...
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose...
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H...
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H...
Medical Care Technologies Inc. (OTC Pink:MDCE) Sees Significant Surge in Investor Activity as Share Structure Stabilizes and New Tech Partnership Forms
MESA, ARIZONA / ACCESS Newswire / December 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is pleased to announce...
Medical Care Technologies (OTC Pink:MDCE) Positions Itself in the Multi-Billion Dollar AI Dermatology Market With Google-Backed Melanoma Detection Technology
MESA, ARIZONA / ACCESS Newswire / December 8, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is thrilled to announce...
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment...
November in Review: 10 Top Health Press Releases
A roundup of the most newsworthy healthcare press releases from PR Newswire, including new company mergers, Alzheimer's fundraising and advances...
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent...
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of...
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable...
Medical Care Technologies Inc. (OTC PINK:MDCE) Expands Development of Consumer-Grade AI Pre-Health Screening Tools Focused on Early Detection
MESA, ARIZONA / ACCESS Newswire / December 2, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) announced today that the...